Merck Sharp & Dohme Corp. v. Dr. Reddy's
- Docket:
- 1:21-cv-01033
Patents:7326708
D. Del. action in which Dr. Reddy's answer admits on its face that the '708 patent is asserted.
Defendant
Dr. Reddy's
1 case as defendant.
- Cases
- 1
- Active
- 0
- 1 closed
- Filed
- —
- Top venue
- D. Delaware
- 1 case
Company profile
I'll research Dr. Reddy's to verify its profile before writing.
Let me verify the litigation context.
Dr. Reddy's Laboratories Limited ("Dr. Reddy's," NYSE ADR: RDY; BSE: 500124; NSE: DRREDDY) is an India-based, publicly listed pharmaceutical company founded in 1984 by Dr. K. Anji Reddy and headquartered at Banjara Hills, Hyderabad, Telangana. It is not a subsidiary; Dr. Reddy's Laboratories, Inc. (New Jersey) is its wholly owned U.S. operating subsidiary, and Dr. Reddy's Laboratories SA is an intermediate parent. Reported headcount is roughly 27,500 (FY2026), with trailing-twelve-month revenue around US$3.6–3.8 billion; it is one of the world's larger generic drug manufacturers.
Operations. The company reports three segments. Global Generics manufactures and markets prescription and OTC finished dosages, branded generics, and biosimilars; North America is its largest generics market. Pharmaceutical Services & Active Ingredients (PSAI) makes APIs and intermediates and provides contract development/manufacturing (CDMO) services. Proprietary Products/Others covers differentiated formulations and novel-biologics R&D. It operates manufacturing and R&D sites in India and abroad and sells in 80+ countries; it also has a consumer-health joint venture with Nestlé. As of March 31, 2026 it reported 347 cumulative U.S. ANDA filings.
Litigation posture. Dr. Reddy's is an operating company, not an NPE. In the case data it appears only as a defendant (0 plaintiff, 1 defendant). The single tracked matter is Merck Sharp & Dohme Corp. v. Dr. Reddy's (D. Del., No. 1:20-cv-00847), a Hatch-Waxman ANDA infringement action under 35 U.S.C. § 271(e)(2) filed June 24, 2020 and terminated October 5, 2021 before Judge Richard G. Andrews. It concerned U.S. Patent 7,326,708 (a dipeptidyl peptidase-IV inhibitor salt, i.e., sitagliptin); Dr. Reddy's answered and counterclaimed. The venue is the District of Delaware — the routine forum for ANDA suits — not a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Context. Because Dr. Reddy's is a large generics filer, Paragraph IV disputes naming it are frequent; the single tracked record here likely reflects a narrow database scope rather than the company's full litigation docket. Its litigation exposure is defense-side generic-entry risk, not patent assertion.